During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed ...

Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...

Medically reviewed by Doru Paul, MD Leukemia is a cancer that changes blood cells. It usually develops in the bone marrow, ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated ...

Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of ...

Carlsbad resident Jim Plotkin was diagnosed with leukemia back in 2018. While going through treatment, he continued to play ...

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel ...

Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia Sep. 17, 2024 — According to new research, 80% of patients with previously untreated or relapsed/refractory ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...